Skip to content
Accretion Pharmaceuticals logo

Accretion Pharmaceuticals

ACCPL NSE
₹206.00 −3.50 (−1.67%)
View as Markdown
MCP
Close 4 Nov 2026 ₹206.00 +150.85 +274% 1Y
Start ₹55.15

Key Fundamentals

SMEPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · TTM

ROCE
28.90%
Debt to Equity
0.23
EPS (TTM)
—
Book Value
₹49.22
Market Cap
—
P/E (TTM)
—
P/B
4.19
ROE
27.60%
Dividend Yield
0.00%
EBITDA
₹15.20 Cr
52W High
₹220.00
52W Low
₹54.60
Day Range
₹205.00 – ₹219.30
Volume
21,600

Peer Comparison

Healthcare › Pharmaceuticals

Accretion Pharmaceuticals peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Accretion Pharmaceuticals (this company)
₹206.00—₹242 Cr4.190.00%27.60%28.90%——
Median 8 companies₹1,587.7038.81₹1,25,337 Cr4.570.44%17.40%19.15%₹28,324 Cr₹3,184 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

56 Good

Data confidence 81/100

surveillance:ESM1

Category scores

Quality
55
Good
Returns, margins, earnings quality 22% weight
Valuation
24
Poor
Cheap vs sector & own history 24% weight
Growth
94
Strong
Sales & profit trajectory 9% weight
Financial Health
67
Strong
Solvency, leverage, coverage 9% weight
Momentum
99
Strong
Trend strength, vol-adjusted 12% weight
Ownership
66
Strong
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has a good return on equity (ROE) track record: 3 Years ROE 35.3%

Weaknesses

2
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company might be capitalizing the interest cost

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish2512
OscillatorsNeutral252
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
58.21
Neutral
MACD (12,26,9)
−0.15
Bullish
SMA (50)
200.37
Bullish
SMA (200)
132.39
Bullish

As of

Growth Rate

From the financial statements below. 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
1Y+56.20%

Net profit

Net profit growth by window
1Y+42.42%

Operating cash flow

Operating cash flow growth by window
1YOutflow widened by ₹13.91 Cr

Operating margin· change in pp

Operating margin growth by window
1Y−4.02 pp

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

Revenue by year

Revenue by year, ₹ crore
Mar 2024₹13.35 Cr
Mar 2025₹57.38 Cr
Mar 2026₹89.63 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2024₹1.49 Cr
Mar 2025₹6.79 Cr
Mar 2026₹9.67 Cr

Half-yearly Results

₹ Cr
ACCPL half-yearly results, ₹ crore
Particulars Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026
Sales
13.35
18.56
38.81
43.74
45.89
Expenses
10.78
14.23
31.27
36.67
38.01
Operating Profit
2.57
4.33
7.54
7.07
7.88
OPM %
19.25%
23.33%
19.43%
16.16%
17.17%
Other Income
0.05
0.02
0.08
0.11
0.08
Interest
0.4
0.69
0.74
0.37
0.48
Depreciation
0.22
0.37
0.41
0.4
0.81
PBT
2
3.29
6.47
6.41
6.67
Tax %
25%
25.23%
33.08%
25.9%
26.24%
Net Profit
1.49
2.46
4.33
4.75
4.92
EPS (₹)
1.96
3.01
5.3
4.27
4.43

Profit & Loss

₹ Cr
ACCPL profit and loss, annual, ₹ crore
Particulars Mar 2024Mar 2025Mar 2026
Sales
13.35
57.38
89.63
Expenses
10.78
45.49
74.66
Operating Profit
2.57
11.89
14.97
OPM %
19.25%
20.72%
16.7%
Other Income
0.05
0.09
0.19
Interest
0.4
1.44
0.87
Depreciation
0.22
0.77
1.21
PBT
2
9.77
13.08
Tax %
25%
30.4%
26.15%
Net Profit
1.49
6.79
9.67
EPS (₹)
1.96
8.31
8.7
Div. Payout %
0%
0%
0%

Balance Sheet

₹ Cr
ACCPL balance sheet, annual, ₹ crore
Particulars Mar 2024Mar 2025Mar 2026
Equity Capital
4
8.17
11.12
Reserves
1.49
7.12
43.59
Borrowings
13.48
14.1
12.32
Other Liabilities
8.47
10.48
9.65
Total Liabilities
27.44
39.87
76.68
Fixed Assets
5.25
6.09
13.21
CWIP
0
0
0.2
Investments
0
0
0
Other Assets
22.19
33.78
63.27
Total Assets
27.44
39.87
76.68

Cash Flow

₹ Cr
ACCPL cash flow, annual, ₹ crore
Particulars Mar 2024Mar 2025Mar 2026
Operating
−11.51
−0.62
−14.53
Investing
−5.48
−1.61
−8.53
Financing
17.08
2.19
27.04
Net Cash Flow
0.09
−0.04
3.97
Free Cash Flow
−16.99
−2.23
−23.06
CFO/EBITDA
−479
18
−75

Ratios

ACCPL financial ratios, annual
Particulars Mar 2024Mar 2025Mar 2026
Debtor Days
159
74.17
91.22
Inventory Days
564
188
159
Days Payable
256
69.41
32.32
Cash Conversion Cycle
466
193
218
Working Capital Days
189
64.69
145
ROCE %
—
46.36%
28.94%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Accretion Pharmaceuticals insights

57 extracted metrics across FY22–FY26.

Shareholding Pattern

As of Sep 2026

  • Promoters 73.52%
  • Public 18.21%
  • Others 4.45%
  • DIIs 3.65%
  • FIIs 0.17%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Accretion Pharmaceuticals

What does Accretion Pharmaceuticals Ltd do?
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.
Where is Accretion Pharmaceuticals Ltd (ACCPL) listed?
Accretion Pharmaceuticals Ltd trades as ACCPL on the NSE.
Which sector does Accretion Pharmaceuticals Ltd belong to?
Accretion Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Accretion Pharmaceuticals Ltd?
Over the last 52 weeks Accretion Pharmaceuticals Ltd has traded between ₹54.6 and ₹220 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Accretion Pharmaceuticals Ltd?
Accretion Pharmaceuticals Ltd reported a return on equity of 27.60%. Its debt-to-equity ratio is 0.23.

Company Information

Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.

Website accretionpharma.com
Listed 21 May 2025
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ACCPL.md for Accretion Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month